


(I),

and has a fed to fasted ratio lower than at least about 2.

47. The method of claim 46, wherein the fed to fasted ratio is less than about 1.5.

48. The method of claim 46, wherein the fed to fasted ratio is less than about 1.0.

49. The method of claim 46, wherein the fed to fasted ratio is less than about 0.75.

50. The method of claim 46, wherein the formulation is in a form of a capsule.


51. The method of claim 46, wherein the formulation is in a form of a solubilized capsule.

52. ~~A method of treating an HCV infection comprising the step of administering to a subject in need thereof~~ Use of a therapeutically effective amount of the formulation of claim 1 in the manufacture of a medicament for treating an HCV infection.

53. ~~A method of treating an HCV infection comprising the step of administering to a subject in need thereof~~ Use of a therapeutically effective amount of the formulation of claim 11 in the manufacture of a medicament for treating an HCV infection.

54. ~~A method of treating an HCV infection comprising the step of administering to a subject in need thereof~~ Use of a formulation comprising a capsule comprising at least one active pharmaceutical ingredient comprising a solubilized compound having the

formula (I)




(I),

wherein the total dose of the compound of formula (I) administered to the subject is about 200 mg a day, in the manufacture of a medicament for treating an HCV infection.

55. The ~~method~~ use of claim 54 wherein the compound of formula (I) is administered to the subject in doses of 100 mg two times a day.


56. ~~A method of treating an HCV infection comprising the step of administering to a subject in need thereof~~ Use of a formulation comprising a capsule comprising at least one active pharmaceutical ingredient comprising a solubilized compound having the formula (I)



(I),

wherein the total dose of the compound of formula (I) administered to the subject is about 150 mg a day, in the manufacture of a medicament for treating an HCV infection.


57. A ~~method of treating an HCV infection comprising the step of administering to a subject in need thereof~~ Use of a formulation comprising a capsule comprising at least one active pharmaceutical ingredient comprising a solubilized compound having the formula (I)



(I),

wherein the total dose of the compound of formula (I) administered to the subject is about 100 mg a day, in the manufacture of a medicament for treating an HCV infection.

58. ~~A method of treating an HCV infection comprising the step of administering to a subject in need thereof~~ Use of a formulation comprising a capsule comprising at least one active pharmaceutical ingredient comprising a solubilized compound having the formula (I)



(I),

wherein the total dose of the compound of formula (I) administered to the subject is about 50 mg a day, in the manufacture of a medicament for treating an HCV infection.